Sam W. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sam W. Lee has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Sarah A. Boswell
Laboratory of Systems Pharmacology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, USA
3 shared publications Pat P. Ongusaha
Cutaneous Biology Research Center (CBRC) Massachusetts General Hospital Harvard Medical School 02129 Charlestown Massachusetts
2 shared publications- Alka Mahale
King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia
1 shared publication Anna Mandinova
Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA, USA
1 shared publication- Anne J. Ridley
School of Biochemistry and Biomedical Sciences, University of Bristol, Biomedical Sciences Building, Bristol, UK.
1 shared publication - Channing J. Der
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
1 shared publication
Latest Publications
- Open Access
- 1 May 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (19) , 13063-13069
Novel Oxidative Stress-responsive Gene ERS25 Functions as a Regulator of the Heat-shock and Cell Death Response
- 1 May 2008
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 283 (19) , 13063-13069
Open AccessNovel Oxidative Stress-responsive Gene ERS25 Functions as a Regulator of the Heat-shock and Cell Death Response
- 1 March 2008
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (5) , 1417-1426
Clonal Selection in Malignant Transformation of Human Fibroblasts Transduced with Defined Cellular Oncogenes
Recent evidence has implied that disruption of a limited number of defined cellular pathways is necessary and sufficient for neoplastic conversion of a variety of normal human cell types in tissue culture. We show instead that malignancy in such models results from an iterative process of clonal selection in vitro and/or in vivo. Normal human fibroblasts underwent malignant transformation after transduction with telomerase, cyclin-dependent kinase 4, dominant-negative p53, and activated Ras or MEK. Furthermore, culture conditions favoring overgrowth resulted in clonal selection, which with added Ras or MEK oncogenes led to the emergence of tumorigenic clones. Such tumors showed variable degrees of malignancy with some even exhibiting metastasis. SV40 small t antigen (ST) has been reported to be necessary and sufficient to convert human fibroblasts with these pathway aberrations to a polyclonal tumor. However, we observed that clonal tumors emerged even with ST addition. Genomic instability was markedly increased by p53 and Rb pathway abrogation. Under the same conditions, fibroblasts with these alterations failed to induce tumors, implying that genomic instability may be necessary but not sufficient for malignant transformation. These findings indicate that the minimum number of events required for malignant transformation of human fibroblasts is greater than has been enumerated by such oncogene addition strategies and support a stochastic cancer progression model initiated by four defined cellular alterations. [Cancer Res 2008;68(5):1417–26]
- 1 March 2008
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 68 (5) , 1417-1426
Clonal Selection in Malignant Transformation of Human Fibroblasts Transduced with Defined Cellular Oncogenes
Recent evidence has implied that disruption of a limited number of defined cellular pathways is necessary and sufficient for neoplastic conversion of a variety of normal human cell types in tissue culture. We show instead that malignancy in such models results from an iterative process of clonal selection in vitro and/or in vivo. Normal human fibroblasts underwent malignant transformation after transduction with telomerase, cyclin-dependent kinase 4, dominant-negative p53, and activated Ras or MEK. Furthermore, culture conditions favoring overgrowth resulted in clonal selection, which with added Ras or MEK oncogenes led to the emergence of tumorigenic clones. Such tumors showed variable degrees of malignancy with some even exhibiting metastasis. SV40 small t antigen (ST) has been reported to be necessary and sufficient to convert human fibroblasts with these pathway aberrations to a polyclonal tumor. However, we observed that clonal tumors emerged even with ST addition. Genomic instability was markedly increased by p53 and Rb pathway abrogation. Under the same conditions, fibroblasts with these alterations failed to induce tumors, implying that genomic instability may be necessary but not sufficient for malignant transformation. These findings indicate that the minimum number of events required for malignant transformation of human fibroblasts is greater than has been enumerated by such oncogene addition strategies and support a stochastic cancer progression model initiated by four defined cellular alterations. [Cancer Res 2008;68(5):1417–26]
- Open Access
- 28 June 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (14) , 3410-3422
CDIP, a novel pro‐apoptotic gene, regulates TNFα‐mediated apoptosis in a p53‐dependent manner
We have identified a novel pro‐apoptotic p53 target gene named CDIP (Cell Death Involved p53‐target). Inhibition of CDIP abrogates p53‐mediated apoptotic responses, demonstrating that CDIP is an important p53 apoptotic effector. CDIP itself potently induces apoptosis that is associated with caspase‐8 cleavage, implicating the extrinsic cell death pathway in apoptosis mediated by CDIP. siRNA‐directed knockdown of caspase‐8 results in a severe impairment of CDIP‐dependent cell death. In investigating the potential involvement of extrinsic cell death pathway in CDIP‐mediated apoptosis, we found that TNF‐α expression tightly correlates with CDIP expression, and that inhibition of TNF‐α signaling attenuates CDIP‐dependent apoptosis. We also demonstrate that TNF‐α is upregulated in response to p53 and p53 inducing genotoxic stress, in a CDIP‐dependent manner. Consistently, knockdown of TNF‐α impairs p53‐mediated stress‐induced apoptosis. Together, these findings support a novel p53 → CDIP → TNF‐α apoptotic pathway that directs apoptosis after exposure of cells to genotoxic stress. Thus, CDIP provides a new link between p53‐mediated intrinsic and death receptor‐mediated extrinsic apoptotic signaling, providing a novel target for cancer therapeutics aimed at maximizing the p53 apoptotic response of cancer cells to drug therapy.
- 28 June 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (14) , 3410-3422
Open AccessCDIP, a novel pro‐apoptotic gene, regulates TNFα‐mediated apoptosis in a p53‐dependent manner
We have identified a novel pro‐apoptotic p53 target gene named CDIP (Cell Death Involved p53‐target). Inhibition of CDIP abrogates p53‐mediated apoptotic responses, demonstrating that CDIP is an important p53 apoptotic effector. CDIP itself potently induces apoptosis that is associated with caspase‐8 cleavage, implicating the extrinsic cell death pathway in apoptosis mediated by CDIP. siRNA‐directed knockdown of caspase‐8 results in a severe impairment of CDIP‐dependent cell death. In investigating the potential involvement of extrinsic cell death pathway in CDIP‐mediated apoptosis, we found that TNF‐α expression tightly correlates with CDIP expression, and that inhibition of TNF‐α signaling attenuates CDIP‐dependent apoptosis. We also demonstrate that TNF‐α is upregulated in response to p53 and p53 inducing genotoxic stress, in a CDIP‐dependent manner. Consistently, knockdown of TNF‐α impairs p53‐mediated stress‐induced apoptosis. Together, these findings support a novel p53 → CDIP → TNF‐α apoptotic pathway that directs apoptosis after exposure of cells to genotoxic stress. Thus, CDIP provides a new link between p53‐mediated intrinsic and death receptor‐mediated extrinsic apoptotic signaling, providing a novel target for cancer therapeutics aimed at maximizing the p53 apoptotic response of cancer cells to drug therapy.
- Open Access
- 1 February 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (7) , 4850-4858
The Protective Role of a Small GTPase RhoE against UVB-induced DNA Damage in Keratinocytes
- 1 February 2007
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 282 (7) , 4850-4858
Open AccessThe Protective Role of a Small GTPase RhoE against UVB-induced DNA Damage in Keratinocytes
- Retracted
- 1 December 2006
- Published by Elsevier in Current Biology
- Vol. 16 (24) , 2466-2472
RETRACTED: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress
- 1 December 2006
- Published by Elsevier in Current Biology
- Vol. 16 (24) , 2466-2472
RetractedRETRACTED: RhoE Is a Pro-Survival p53 Target Gene that Inhibits ROCK I-Mediated Apoptosis in Response to Genotoxic Stress